Using the predictive modelling platform, Policy1–Bowel, the team is performing modelled evaluations of the National Bowel Cancer Screening Program (NBCSP) to help guide investment, and support uptake of the program across Australia, aid recovery after disruptions to the program (e.g., COVID-19 or bushfires), and to help inform strategies for targeting vulnerable groups. The team is also performing managing the update to the population screening and family history chapters of the clinical practice guidelines as well as cost-effectiveness evaluations of different approaches to boost participation in the bowel screening program, including mass media campaigns and general practice-led interventions. They are also working as part of the COVID-19 and Cancer Global Modelling Consortium to comparatively model the impact of disruptions to bowel screening caused by COVID-19 internationally.
Our team is leading the MAIL, GP & SCALE project, funding through the National Health and Medical Research Council (2021/GNT2014964). As part of the project, we are leading a national clinical trial to pilot a co-designed general practice-led intervention to increase participation in the National Bowel Cancer Screening Program (NBCSP).
The findings of the trial will be combined with other individual and population-level strategies shown to increase participation in the NBCSP to determine which combination of interventions are most effective to support bowel cancer screening across Australia. Results will be available in early 2026.